Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. This is an ASCO ...

Oregon Health & Science University researchers have developed a first-of-its-kind method to predict cancer patient survival ...

In the ARROW trial, researchers found that different RET fusion partners affected the durability of patients' responses, a finding that could be useful for guiding treatment.

Our study is motivated by evaluating the role of hematopoietic cell transplantation (HCT) after chimeric antigen receptor T-cell (CAR-T) therapy for ALL, a debated topic. Because patients may receive ...

The first overall survival analysis of the KEYNOTE-522 trial showed positive outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy vs neoadjuvant ...